ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2131

Time-course Analysis from the First Wave to Early 2023 in Critically Ill Patients with Novel Coronavirus Infection in Rheumatoid Arthritis

MASAOMI YAMASAKI, Shin-Yokohama Arthritis and Rheumatology Clinic, Yokohama, Japan

Meeting: ACR Convergence 2023

Keywords: COVID-19, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2095–2140) RA – Diagnosis, Manifestations, and Outcomes Poster III

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: We analyzed trends in the incidence and severity of novel coronavirus disease (COVID-19) from the first wave to early 2023 in patients with rheumatoid arthritis (RA).

Methods: Cases who were diagnosed according to ACR/EULAR 2010 classification criteria were recruited to SHin-yokohama Arthritis REgister (SHARE) between 2020 and 2023. We conducted a retrospective cohort study investigating COVID-19 outcomes in clinic-confirmed rheumatoid arthritis patients from March 1, 2020 to February 28, 2023. We aggregated the total number of COVID-19 cases and the number of critically ill cases (hospitalized or died) and calculated the number of severe cases of COVID-19 by calendar period. compared the proportions. We estimated the clinical features of severe COVID-19 in each period. Rheumatic Disease Comorbidity Index (RDCI) were analyzed to detect the clinical features of severe COVID-19 in RA patients.

Results: 2,481 RA patients were enrolled. 316 cases were diagnosed as COVID-19 (12.8%, average age 57.8+/-12.8 years, female 84.5%). There were 7 cases of severe COVID-19 (2.2%). The proportion of serious outcomes due to COVID-19 decreased over calendar time (p < 0.0001). 16% of cases were severe in the early stage of COVID-19 (March 1, 2020-November 30, 2021), compared with after omicron stages (December 1, 2021-February 28, 2023) was 1.0%.

In the early stage of COVID-19, elderly age (p=0.0054), hypertension (p=0.0021), diabetes (p=0.0291) and RDCI (1.5+/-1.3 vs. 0.4+/-0.7, p=0.0388) were associated with critical ill cases. After omicron stages of COVID-19, elderly age (p=0.0292), hypertension (p=0.0006), RA-ILD (p< 0.0001) and RDCI (4.0+/-2.6 vs. 0.4+/-0.8, p=0.0002) were associated with critical ill cases.

Conclusion: CONCLUSIONS Although the proportion of severe COVID-19 RA cases has decreased in after omicron stages compared to early stages of COVID-19, the clinical features of severe COVID-19 were very similar between two groups.

Supporting image 1

Patient characteristic of COVID_19 in RA

Supporting image 2

The clinical features of severe COVID_19 in the early stage (March 1, 2020-November 30, 2021)

Supporting image 3

The clinical features of severe COVID_19 in the after omicron stage (December 1, 2021-February 28, 2023)


Disclosures: M. YAMASAKI: None.

To cite this abstract in AMA style:

YAMASAKI M. Time-course Analysis from the First Wave to Early 2023 in Critically Ill Patients with Novel Coronavirus Infection in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/time-course-analysis-from-the-first-wave-to-early-2023-in-critically-ill-patients-with-novel-coronavirus-infection-in-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/time-course-analysis-from-the-first-wave-to-early-2023-in-critically-ill-patients-with-novel-coronavirus-infection-in-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology